Brownlee Center, Gartnavel General Hospital, Glasgow, Scotland.
Infect Drug Resist. 2011;4:115-27. doi: 10.2147/IDR.S13808. Epub 2011 May 24.
Skin and soft tissue infections (SSTIs) are the second most common infection encountered in hospitals. Management decisions have become increasingly complex due to the prevalence of resistant pathogens, the wide array of licensed antimicrobials and the availability of potent oral agents and of out-patient parenteral antibiotic therapy. Daptomycin is one of the newer therapeutic agents licensed for complex SSTI management. Rapid cidality, good soft tissue penetration, once daily IV bolus administration and activity against resistant Gram-positive infections make daptomycin an attractive option both in hospitalized and community treated patients. A comprehensive review of the evidence for and experience with daptomycin and its use in SSTIs is presented.
皮肤和软组织感染（SSTIs）是医院中第二大常见感染。由于耐药病原体的流行、广泛的许可抗菌药物以及强效口服药物和门诊肠外抗生素治疗的可用性，管理决策变得越来越复杂。达托霉素是一种新型治疗药物，被许可用于复杂 SSTI 的管理。达托霉素具有快速杀菌作用、良好的软组织穿透力、每日一次静脉推注给药以及对耐药革兰阳性感染的活性，使其成为住院和社区治疗患者的一个有吸引力的选择。本文全面回顾了达托霉素的证据和经验及其在 SSTIs 中的应用。
